Opin vísindi

Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia : A long-term nationwide study

Show simple item record

dc.contributor Landspitali - The National University Hospital of Iceland
dc.contributor.author Rögnvaldsson, Kristján G
dc.contributor.author Bjarnason, Agnar
dc.contributor.author Kristinsson, Karl
dc.contributor.author Bragason, Hörður T
dc.contributor.author Erlendsdóttir, Helga
dc.contributor.author Þorgeirsson, Guðmundur
dc.contributor.author Gottfreðsson, Magnús
dc.date.accessioned 2022-05-25T01:02:54Z
dc.date.available 2022-05-25T01:02:54Z
dc.date.issued 2022-03-21
dc.identifier.citation Rögnvaldsson , K G , Bjarnason , A , Kristinsson , K , Bragason , H T , Erlendsdóttir , H , Þorgeirsson , G & Gottfreðsson , M 2022 , ' Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia : A long-term nationwide study ' , Journal of Internal Medicine . https://doi.org/10.1111/joim.13485
dc.identifier.issn 0954-6820
dc.identifier.other PURE: 49026544
dc.identifier.other PURE UUID: b24fb09c-91d7-47c8-9f71-cbaa8258c29f
dc.identifier.other unpaywall: 10.1111/joim.13485
dc.identifier.other Scopus: 85127596977
dc.identifier.uri https://hdl.handle.net/20.500.11815/3197
dc.description © 2022 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. Funding Information: The Icelandic Centre for Research (Rannís, grant number 217716‐051), The Doctoral Grants of The University of Iceland Research Fund, The Scientific Fund of Landspitali—The National University Hospital of Iceland, The Scandinavian Society for Antimicrobial Chemotherapy Foundation and the Foundation of St. Josef´s Hospital funded Kristján Godsk Rögnvaldsson´s work on this project. The funding sources had no role in the study's design, conduct, or reporting. Publisher Copyright: © 2022 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
dc.description.abstract BACKGROUND: Pneumonia is commonly caused by Streptococcus pneumoniae (pneumococcus) and associated with subsequent cardiovascular complications and increased mortality. Potential short-term survival benefits conferred by acetylsalicylic acid (ASA) use in pneumonia remain controversial, and long-term outcomes have not been studied. OBJECTIVES: To evaluate the association between ASA use and survival for up to 1 year following bacteremic pneumococcal pneumonia. METHODS: All bacteremic pneumococcal episodes in Iceland from 1975 to 2019 were reviewed. The study cohort consisted of individuals at least 18 years of age with symptoms and imaging results consistent with pneumonia. Differences in survival were assessed at 30 days, 90 days and 1 year using propensity score weighting (inverse probability weighting). Splitting and stratifying on survival at 7 days was done for the 30-day survival, because of nonproportionality. RESULTS: In total, 815 bacteremic pneumococcal pneumonia episodes (median age 67 years, females 48%) were identified. Cox regression using propensity score weighting on the association of ASA with survival at 30 days showed an average hazard ratio (HR) of 0.60 (95% confidence interval [CI] 0.34-1.05). A significantly improved survival was observed within 7 days (HR = 0.42, 95% CI 0.19-0.92) but not during days 7-30 (HR = 1.08, 95% CI 0.46-2.55). ASA was associated with survival at 90 days (HR = 0.53, 95% CI 0.32-0.87) and 1 year (HR = 0.48, 95% CI 0.31-0.75). CONCLUSION: Use of ASA upon admission for bacteremic pneumococcal pneumonia is associated with significantly reduced mortality for up to 1 year after diagnosis. ASA therapy in patients with pneumonia and other infectious syndromes warrants further study.
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries Journal of Internal Medicine; ()
dc.rights info:eu-repo/semantics/openAccess
dc.subject Smitsjúkdómalæknisfræði
dc.subject Náttúrufræðingar
dc.subject Hjartalæknisfræði
dc.subject Vísindadeild
dc.subject Pneumókokkar
dc.subject Lungnabólga
dc.subject Aspirín
dc.subject Lífslíkur
dc.subject Streptococcus pneumoniae
dc.subject aspirin
dc.subject pneumonia
dc.subject population-based
dc.subject survival
dc.title Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia : A long-term nationwide study
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.pmid 35315156
dc.identifier.doi https://doi.org/10.1111/joim.13485
dc.relation.url http://www.scopus.com/inward/record.url?scp=85127596977&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine
dc.contributor.department Internal Medicine and Emergency Services
dc.contributor.department Clinical Laboratory Services, Diagnostics and Blood Bank
dc.contributor.department Cardio-Vascular Center
dc.contributor.department Other departments


Files in this item

This item appears in the following Collection(s)

Show simple item record